Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.

Abstract: This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug.

Abstract: In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.

Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.

Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.

Abstract: Compositions and method are disclosed comprising ethyl icosapentate for use in treatment of non-alcoholic steatohepatitis (NASH).

Abstract: A novel convenient method for evaluating the function of a phagocyte is provided. The method assays sCD14-ST, which is a humoral factor specifically produced in phagocytosis by the phagocyte and which is stable enough for use in an assay. Also provided is a method for detecting diseases associated with the phagocytosis by the phagocyte.

Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.

Abstract: A composition in which a preparation of the composition itself has an excellent disintegratability in the right place and excellent active ingredient releasability within the digestive tract, the active ingredient and the preparation itself have long-term stability, excellent ease of operation such as manufacturability and filling into containers, an amount sufficient for achieving physiological effects can be easily taken and swallowed, and can be absorbed rapidly from the digestive tract, thus the physiological effect can be expected. The composition is an easy-release jelly composition containing an emulsified polyvalent unsaturated fatty acid or derivative thereof in an amount exceedingly 10 mass % and further containing an emulsifying agent and a gallant. The easy-release jelly composition includes an emulsified polyunsaturated fatty acid or derivative thereof in an amount greater than 10 wt %, an emulsifying agent, and a gelling agent.

Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.

Abstract: It has been desired to develop a pharmaceutical composition, which is used in agents for preventing and/or treating various diseases related to PDE10 (e.g. mental disorder and neurodegenerative disorder). The present invention provides: compounds having PDE10 inhibitory effect, in particular, compounds having a 4-heteroarylpyrazole-5-carboxylic acid amide structure represented by the following formula (I), or their pharmaceutically acceptable salts, or their solvates; pharmaceutical compositions comprising, as active ingredients, the compounds, or their pharmaceutically acceptable salts, or their solvates; and medical use of the compounds, or their pharmaceutically acceptable salts, or their solvates.

Abstract: Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.

Abstract: A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100 mass %, 70 to 90 mass % of at least one compound selected from the group consisting of ?3 polyunsaturated fatty acids, pharmaceutically acceptable salts thereof, and esters of the same, 0.5 to 6 mass % of water and 1 to 29 mass % of an emulsifying agent that comprises a polyoxyethylene sorbitan fatty acid ester (and that further contains a polyoxyl castor oil optionally, with the proviso that the emulsifying agent does not include lecithin) and which contains 3 to 40 parts by mass of lecithin relative to 100 parts by weight of the ?3 polyunsaturated fatty acid or the like. This self-emulsifying composition exhibits excellent self-emulsifying properties, composition dispersibility, emulsion stability and absorbability, and does not contain ethanol or a polyhydric alcohol or contains the same only in a low concentration. The self-emulsifying composition is useful for food and medicine.

Abstract: A self-emulsifying composition contains: 70 to 90% by weight in total of one or more compounds selected from the group consisting of ?3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; 1 to 29% by weight of an emulsifying agent selected from among a polyoxyethylene sorbitan fatty acid ester, a sorbitan fatty acid ester, a glycerin fatty acid ester and a polyoxyl castor oil; and 0.5 to 6% by weight of water when the composition is defined to be 100% by weight as a whole. The self-emulsifying composition is excellent in self-emulsifying property, composition dispersibility, emulsion stability, and absorbability, is free from ethanol and polyhydric alcohols or only has such an alcohol added thereto at a reduced concentration, and is useful for foods and pharmaceuticals.

Abstract: The present invention provides an agent for preventing the increase in a body weight (or for decreasing a body weight) or an anti-obesity agent each comprising at least one component selected from the group consisting of EPA and pharmaceutically acceptable salts, esters and derivatives thereof as an active ingredient for obesity in which the increase in the formation of hepatic lipid or the occurrence of fatty liver is mild, preferably the increase in the formation of hepatic lipid or the occurrence of fatty liver is not observed.

Abstract: Provided is FGF21 that is a metabolism-related biomarker reflecting the activation of Nrf2 in vivo. Also provided are a method for monitoring a response of a subject to which an Nrf2 activator is administered, said method comprising a step for measuring the FGF21 level, at a point during or after the administration of the Nrf2 activator, in a biosample that is derived from the subject, wherein an increase in the FGF21 level indicates a positive response to the administration of the Nrf2 activator, etc. According to the present invention, a metabolism-related biomarker that reflects the activation of Nrf2 in vivo is provided.

Abstract: Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient.

Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the urine sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.

Abstract: According to the method for detecting respiratory infection associated with bacterial infection of the present invention, the measured value of soluble CD14 antigen subtype (“sCD14-ST) in the blood sample can be used to select a patient with a respiratory infection to whom the antibiotic can be administered.